Keywords
Last Name
Institution

Massimo Cristofanilli

TitleProfessor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-955-8874
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Mu Z, Wang C, Ye Z, Rossi G, Sun C, Li L, Zhu Z, Yang H, Cristofanilli M. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. Breast Cancer Res Treat. 2017 Jul 07. PMID: 28687903.
      View in: PubMed
    2. Paolillo C, Mu Z, Rossi G, Schiewer MJ, Nguyen T, Austin L, Capoluongo E, Knudsen KE, Cristofanilli M, Fortina P. Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells. Clin Cancer Res. 2017 Jul 05. PMID: 28679775.
      View in: PubMed
    3. Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, Masuda N, Loi S, André F, Harbeck N, Verma S, Folkerd E, Theall KP, Hoffman J, Zhang K, Bartlett CH, Dowsett M. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist. 2017 Jun 26. PMID: 28652278.
      View in: PubMed
    4. Schott AF, Goldstein L, Cristofanilli M, Ruffini PA, McCanna S, Reuben JM, Perez R, Kato G, Wicha MS. Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC). Clin Cancer Res. 2017 May 24. PMID: 28539464.
      View in: PubMed
    5. Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. Clin Cancer Res. 2017 Apr 26. PMID: 28446508.
      View in: PubMed
    6. Bingham C, Fernandez SV, Fittipaldi P, Dempsey PW, Ruth KJ, Cristofanilli M, Katherine Alpaugh R. Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients. Breast Cancer Res Treat. 2017 Jun; 163(2):219-230. PMID: 28271309.
      View in: PubMed
    7. Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D, Carneiro BA, Chae YK, Cristofanilli M, Gradishar WJ, Giles FJ. Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. Cancer Treat Rev. 2017 Feb; 53:111-119. PMID: 28104566.
      View in: PubMed
    8. Shah AN, Cristofanilli M. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. Curr Treat Options Oncol. 2017 Jan; 18(1):6. PMID: 28197838.
      View in: PubMed
    9. Costa R, Santa-Maria CA, Rossi G, Carneiro BA, Chae YK, Gradishar WJ, Giles FJ, Cristofanilli M. Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget. 2016 Dec 02. PMID: 27926493.
      View in: PubMed
    10. Cristofanilli M. Metastatic breast cancer: focus on endocrine sensitivity. Lancet. 2016 12 17; 388(10063):2961-2962. PMID: 27908455.
      View in: PubMed
    11. Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WH, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proc Natl Acad Sci U S A. 2016 Oct 24. PMID: 27791177.
      View in: PubMed
    12. Lin J, Patel SA, Sama AR, Hoffman-Censits JH, Kennedy B, Kilpatrick D, Ye Z, Yang H, Mu Z, Leiby B, Lewis N, Cristofanilli M, Kelly WK. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. Oncologist. 2016 Nov; 21(11):1296-1297e. PMID: 28178640.
      View in: PubMed
    13. Wang C, Mu Z, Chervoneva I, Austin L, Ye Z, Rossi G, Palazzo JP, Sun C, Abu-Khalaf M, Myers RE, Zhu Z, Ba Y, Li B, Hou L, Cristofanilli M, Yang H. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Cancer Res Treat. 2017 Jan; 161(1):83-94. PMID: 27771841.
      View in: PubMed
    14. Mu Z, Benali-Furet N, Uzan G, Znaty A, Ye Z, Paolillo C, Wang C, Austin L, Rossi G, Fortina P, Yang H, Cristofanilli M. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer. Int J Mol Sci. 2016 Sep 30; 17(10). PMID: 27706044.
      View in: PubMed
    15. Johnston S, Basik M, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M, Dreosti L, Mann H, Stuart M, Cristofanilli M. Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. Breast Cancer Res Treat. 2016 Nov; 160(1):91-99. PMID: 27654971.
      View in: PubMed
    16. Toss A, Palazzo J, Berger A, Guiles F, Sendecki JA, Simone N, Anne R, Avery T, Jaslow R, Lazar M, Tsangaris T, Cristofanilli M. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less. Breast. 2016 Oct; 29:223-30. PMID: 27506636.
      View in: PubMed
    17. Zhang S, Li L, Wang T, Bian L, Hu H, Xu C, Liu B, Liu Y, Cristofanilli M, Jiang Z. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. BMC Cancer. 2016; 16(1):526. PMID: 27456503.
      View in: PubMed
    18. Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, Cryns VL, Mazar AP. GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett. 2016 Oct 1; 380(2):384-92. PMID: 27424289.
      View in: PubMed
    19. Joyce BT, Gao T, Zheng Y, Liu L, Zhang W, Dai Q, Shrubsole MJ, Hibler EA, Cristofanilli M, Zhang H, Yang H, Vokonas P, Cantone L, Schwartz J, Baccarelli A, Hou L. Prospective changes in global DNA methylation and cancer incidence and mortality. Br J Cancer. 2016 Aug 9; 115(4):465-72. PMID: 27351216.
      View in: PubMed
    20. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 2016 Jun 25. PMID: 27374101.
      View in: PubMed
    21. Adams DL, Adams DK, Alpaugh RK, Cristofanilli M, Martin SS, Chumsri S, Tang CM, Marks JR. Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. Cancer Epidemiol Biomarkers Prev. 2016 Jul; 25(7):1037-42. PMID: 27197300.
      View in: PubMed
    22. Adams DL, Adams DK, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK. Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas. Breast Cancer Res. 2016; 18(1):44. PMID: 27142282.
      View in: PubMed
    23. Hamm CA, Moran D, Rao K, Trusk PB, Pry K, Sausen M, Jones S, Velculescu VE, Cristofanilli M, Bacus S. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Mol Cancer Ther. 2016 Jul; 15(7):1746-56. PMID: 27196778.
      View in: PubMed
    24. Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, Giles FJ. Is Personalized Medicine Here? Oncology (Williston Park). 2016 Apr 15; 30(4). PMID: 27085327.
      View in: PubMed
    25. Cristofanilli M. Inflammatory breast cancer: a new approach. Lancet Oncol. 2016 May; 17(5):544-6. PMID: 27032300.
      View in: PubMed
    26. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr; 17(4):425-39. PMID: 26947331.
      View in: PubMed
    27. Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu CG, Liu X, Lin F, Symmans WF, Wei W, Zhang X, Sun L, Alvarez RH, Ueno NT, Fouad TM, Harano K, Debeb BG, Wu Y, Reuben J, Cristofanilli M, Zuo Z. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol. 2016 Apr; 29(4):330-46. PMID: 26916073.
      View in: PubMed
    28. Ogony J, Choi HJ, Lui A, Cristofanilli M, Lewis-Wambi J. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner. Breast Cancer Res. 2016; 18(1):25. PMID: 26897526.
      View in: PubMed
    29. Gogoi P, Sepehri S, Zhou Y, Gorin MA, Paolillo C, Capoluongo E, Gleason K, Payne A, Boniface B, Cristofanilli M, Morgan TM, Fortina P, Pienta KJ, Handique K, Wang Y. Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. PLoS One. 2016; 11(1):e0147400. PMID: 26808060.
      View in: PubMed
    30. Jiao X, Rizvanov AA, Cristofanilli M, Miftakhova RR, Pestell RG. Breast Cancer Stem Cell Isolation. Methods Mol Biol. 2016; 1406:121-35. PMID: 26820950.
      View in: PubMed
    31. Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Res Treat. 2015 Dec; 154(3):563-71. PMID: 26573830.
      View in: PubMed
    32. Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Oct 22; 373(17):1672-3. PMID: 26488700.
      View in: PubMed
    33. Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, Cristofanilli M. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Res Treat. 2015 Nov; 154(1):155-62. PMID: 26458824.
      View in: PubMed
    34. Wurth R, Tarn K, Jernigan D, Fernandez SV, Cristofanilli M, Fatatis A, Meucci O. A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process. Transl Oncol. 2015 Oct; 8(5):358-67. PMID: 26500026.
      View in: PubMed
    35. Yao K, Goldschmidt R, Turk M, Wesseling J, Stork-Sloots L, de Snoo F, Cristofanilli M. Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. Breast Cancer Res Treat. 2015 Nov; 154(1):81-8. PMID: 26424167.
      View in: PubMed
    36. Terai M, Mu Z, Eschelman DJ, Gonsalves CF, Kageyama K, Chervoneva I, Orloff M, Weight R, Mastrangelo MJ, Cristofanilli M, Sato T. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells. EBioMedicine. 2015 Nov; 2(11):1821-6. PMID: 26870807.
      View in: PubMed
    37. Lai Y, Ye Z, Civan JM, Wang C, Cristofanilli M, Mu Z, Austin L, Palazzo JP, Myers RE, Yang H. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study. Breast Cancer Res Treat. 2015 Sep; 153(2):407-16. PMID: 26264468.
      View in: PubMed
    38. Cohen EN, Gao H, Anfossi S, Mego M, Reddy NG, Debeb B, Giordano A, Tin S, Wu Q, Garza RJ, Cristofanilli M, Mani SA, Croix DA, Ueno NT, Woodward WA, Luthra R, Krishnamurthy S, Reuben JM. Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS One. 2015; 10(7):e0132710. PMID: 26207636.
      View in: PubMed
    39. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600.
      View in: PubMed
    40. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015 Aug 20; 33(24):2695-704. PMID: 26195705.
      View in: PubMed
    41. Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol. 2015 Jun; 38(3):242-7. PMID: 23648437.
      View in: PubMed
    42. Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16; 373(3):209-19. PMID: 26030518.
      View in: PubMed
    43. Dawood S, Cristofanilli M. Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies? Pharmacogenomics. 2015 May; 16(7):669-72. PMID: 25950463.
      View in: PubMed
    44. Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, Hatzis C, Hudis CA, Pedrazzoli P, Sapino A, Semiglazov V, Von Minckwitz G, Simoncini EL, Jacobs MA, Barry P, Kühn T, Darby S, Hermelink K, Symmans F, Gennari A, Schiavon G, Dogliotti L, Berruti A, Bottini A. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). J Natl Cancer Inst Monogr. 2015 May; 2015(51):90-6. PMID: 26063896.
      View in: PubMed
    45. Generali D, Fox SB, Cristofanilli M, Bianchini G, Zambelli A, Hatzis C, Barberis M, Tarricone R, Bottini A, Rossi C, Tringali M. Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. J Natl Cancer Inst Monogr. 2015 May; 2015(51):1-3. PMID: 26063875.
      View in: PubMed
    46. Dawood S, Cristofanilli M. IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model. J Natl Cancer Inst Monogr. 2015 May; 2015(51):56-9. PMID: 26063888.
      View in: PubMed
    47. Toss A, Cristofanilli M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res. 2015; 17(1):60. PMID: 25902832.
      View in: PubMed
    48. Kang SA, Hasan N, Mann AP, Zheng W, Zhao L, Morris L, Zhu W, Zhao YD, Suh KS, Dooley WC, Volk D, Gorenstein DG, Cristofanilli M, Rui H, Tanaka T. Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. Mol Ther. 2015 Jun; 23(6):1044-54. PMID: 25815697.
      View in: PubMed
    49. Mego M, Karaba M, Minarik G, Benca J, Sedlácková T, Tothova L, Vlkova B, Cierna Z, Janega P, Luha J, Gronesova P, Pindak D, Fridrichova I, Celec P, Reuben JM, Cristofanilli M, Mardiak J. Relationship between Circulating Tumor Cells, Blood Coagulation, and Urokinase-Plasminogen-Activator System in Early Breast Cancer Patients. Breast J. 2015 Mar; 21(2):155-60. PMID: 25623304.
      View in: PubMed
    50. Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res. 2015; 17(1):2. PMID: 25572591.
      View in: PubMed
    51. Adams DL, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK. Cytometric characterization of Circulating Tumor Cells Captured by microfiltration and their correlation to the cellsearch(®) CTC test. Cytometry A. 2015 Feb; 87(2):137-44. PMID: 25515318.
      View in: PubMed
    52. Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology (Williston Park). 2014 Dec; 28(12):1101-7, 1110. PMID: 25510809.
      View in: PubMed
    53. Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Andò S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG. CCR5 Receptor Antagonists Block Metastasis to Bone of v-Src Oncogene-Transformed Metastatic Prostate Cancer Cell Lines. Cancer Res. 2014 Dec 1; 74(23):7103-14. PMID: 25452256.
      View in: PubMed
    54. Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, Anfossi S, Jackson S, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Khoury JD, Cristofanilli M, Reuben JM. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost. 2015 Mar; 113(3):593-8. PMID: 25373787.
      View in: PubMed
    55. Toss A, Mu Z, Fernandez S, Cristofanilli M. CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med. 2014 Nov; 2(11):108. PMID: 25489582.
      View in: PubMed
    56. Chand SN, Blanco FF, Jimbo M, Tsangaris TN, Cristofanilli M, Yeo CJ, Winter JM, Pishvaian MJ, Brody JR. PARP Inhibitors for Chemoprevention-Letter. Cancer Prev Res (Phila). 2014 Nov; 7(11):1170-1. PMID: 25368011.
      View in: PubMed
    57. Wang C, Civan J, Lai Y, Cristofanilli M, Hyslop T, Palazzo JP, Myers RE, Li B, Ye Z, Zhang K, Xing J, Yang H. Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables. Cancer Causes Control. 2015 Jan; 26(1):45-56. PMID: 25359303.
      View in: PubMed
    58. Fernandez SV, Bingham C, Fittipaldi P, Austin L, Palazzo J, Palmer G, Alpaugh K, Cristofanilli M. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res. 2014; 16(5):445. PMID: 25307991.
      View in: PubMed
    59. Lai Y, Palazzo JP, Cristofanilli M, Hyslop T, Civan J, Avery T, Myers RE, Li B, Ye Z, Xing J, Yang H. Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy. Breast Cancer Res Treat. 2014 Nov; 148(1):175-85. PMID: 25261294.
      View in: PubMed
    60. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 2014; 16(5):440. PMID: 25223629.
      View in: PubMed
    61. Matro JM, Li T, Cristofanilli M, Hughes ME, Ottesen RA, Weeks JC, Wong YN. Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. Clin Breast Cancer. 2015 Feb; 15(1):1-7. PMID: 25034439.
      View in: PubMed
    62. Mu Z, Klinowska T, Dong X, Foster E, Womack C, Fernandez SV, Cristofanilli M. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res. 2014; 33(1):47. PMID: 24886365.
      View in: PubMed
    63. Woodward WA, Krishnamurthy S, Lodhi A, Xiao L, Gong Y, Cristofanilli M, Buchholz TA, Lucci A. Aldehyde dehydrogenase1 immunohistochemical staining in primary breast cancer cells independently predicted overall survival but did not correlate with the presence of circulating or disseminated tumors cells. J Cancer. 2014; 5(5):360-7. PMID: 24799954.
      View in: PubMed
    64. Cristofanilli M. Circulating tumour cells: telling the truth about metastasis. Lancet Oncol. 2014 Apr; 15(4):365-6. PMID: 24636207.
      View in: PubMed
    65. Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM, Cristofanilli M. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A. 2014 Mar 4; 111(9):3514-9. PMID: 24550495.
      View in: PubMed
    66. Ali SM, Alpaugh RK, Downing SR, Stephens PJ, Yu JQ, Wu H, Buell JK, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2-Targeted Therapy. J Clin Oncol. 2014 Sep 1; 32(25):e88-91. PMID: 24516025.
      View in: PubMed
    67. van Golen KL, Cristofanilli M. The third international inflammatory breast cancer conference. Breast Cancer Res. 2013; 15(6):318. PMID: 24188125.
      View in: PubMed
    68. Robertson FM, Petricoin Iii EF, Van Laere SJ, Bertucci F, Chu K, Fernandez SV, Mu Z, Alpaugh K, Pei J, Circo R, Wulfkuhle J, Ye Z, Boley KM, Liu H, Moraes R, Zhang X, Demaria R, Barsky SH, Sun G, Cristofanilli M. Presence of anaplastic lymphoma kinase in inflammatory breast cancer. Springerplus. 2013; 2:497. PMID: 24102046.
      View in: PubMed
    69. Natori A, Hayashi N, Soejima K, Deshpande GA, Takahashi O, Cristofanilli M, Ueno NT, Yamauchi H. A Comparison of Epidemiology, Biology, and Prognosis of Inflammatory Breast Cancer in Japanese and US Populations. Clin Breast Cancer. 2013 Dec; 13(6):460-4. PMID: 24084032.
      View in: PubMed
    70. Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res. 2013; 32(1):70. PMID: 24294976.
      View in: PubMed
    71. Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib. Clin Breast Cancer. 2014 Feb; 14(1):e14-6. PMID: 24201163.
      View in: PubMed
    72. Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA. Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Res Treat. 2013 Oct; 141(3):429-35. PMID: 24068539.
      View in: PubMed
    73. Cristofanilli M, Fortina P. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013 Jul 4; 369(1):93-4. PMID: 23822789.
      View in: PubMed
    74. Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z, Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S, Cristofanilli M. Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat. 2013 Jul; 140(1):23-33. PMID: 23784380.
      View in: PubMed
    75. Zhang EY, Cristofanilli M, Robertson F, Reuben JM, Mu Z, Beavis RC, Im H, Snyder M, Hofree M, Ideker T, Omenn GS, Fanayan S, Jeong SK, Paik YK, Zhang AF, Wu SL, Hancock WS. Genome Wide Proteomics of ERBB2 and EGFR and Other Oncogenic Pathways in Inflammatory Breast Cancer. J Proteome Res. 2013 Jun 7; 12(6):2805-17. PMID: 23647160.
      View in: PubMed
    76. Woodward WA, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E, Niwa S, Cristofanilli M, Vermeulen P, Dirix L, Viens P, van Laere S, Bertucci F, Reuben JM, Ueno NT. Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(3):761-72. PMID: 23568481.
      View in: PubMed
    77. Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix L, Reuben JM, Bertucci F. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res. 2013 Sep 1; 19(17):4685-96. PMID: 23396049.
      View in: PubMed
    78. Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM, Pierga JY, Cristofanilli M, Bidard FC. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res. 2013 Mar 15; 19(6):1596-602. PMID: 23340302.
      View in: PubMed
    79. Robertson FM, Chu K, Boley KM, Ye Z, Liu H, Wright MC, Moraes R, Zhang X, Green TL, Barsky SH, Heise C, Cristofanilli M. The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis. J Exp Ther Oncol. 2013; 10(3):219-33. PMID: 24416998.
      View in: PubMed
    80. Liu S, Im H, Bairoch A, Cristofanilli M, Chen R, Deutsch EW, Dalton S, Fenyo D, Fanayan S, Gates C, Gaudet P, Hincapie M, Hanash S, Kim H, Jeong SK, Lundberg E, Mias G, Menon R, Mu Z, Nice E, Paik YK, Uhlen M, Wells L, Wu SL, Yan F, Zhang F, Zhang Y, Snyder M, Omenn GS, Beavis RC, Hancock WS. A Chromosome-centric Human Proteome Project (C-HPP) to Characterize the Sets of Proteins Encoded in Chromosome 17. J Proteome Res. 2013 Jan 4; 12(1):45-57. PMID: 23259914.
      View in: PubMed
    81. Cristofanilli M, Johnston SR, Manikhas A, Gomez HL, Gladkov O, Shao Z, Safina S, Blackwell KL, Alvarez RH, Rubin SD, Ranganathan S, Redhu S, Trudeau ME. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):471-82. PMID: 23239151.
      View in: PubMed
    82. Dong X, Alpaugh KR, Cristofanilli M. Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. Chin J Cancer Res. 2012 Dec; 24(4):388-98. PMID: 23359451.
      View in: PubMed
    83. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Mol Cancer Ther. 2012 Nov; 11(11):2526-34. PMID: 22973057.
      View in: PubMed
    84. Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer. 2012; 3:369-80. PMID: 23074378.
      View in: PubMed
    85. Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012; 10:138. PMID: 22747748.
      View in: PubMed
    86. Dawood S, Cristofanilli M. Brain metastasis in breast cancer: last barrier to the cure? Oncology (Williston Park). 2012 Jul; 26(7):664, 666. PMID: 22888568.
      View in: PubMed
    87. De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012 Aug; 12(4):264-9. PMID: 22591634.
      View in: PubMed
    88. Cristofanilli M. Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone. J Oncol. 2012; 2012:703858. PMID: 22645612.
      View in: PubMed
    89. Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA, Woodward WA. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat. 2012 Jul; 134(2):495-510. PMID: 22547109.
      View in: PubMed
    90. Giordano A, Cristofanilli M. CTCs in metastatic breast cancer. Recent Results Cancer Res. 2012; 195:193-201. PMID: 22527507.
      View in: PubMed
    91. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012 May; 19(5):1508-16. PMID: 22193884.
      View in: PubMed
    92. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011; 16(12):1675-83. PMID: 22147002.
      View in: PubMed
    93. Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer. 2012 May 1; 118(9):2378-84. PMID: 22006179.
      View in: PubMed
    94. Dawood S, Shaikh AJ, Buchholz TA, Cortes J, Cristofanilli M, Gupta S, Gonzalez-Angulo AM. The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. Cancer. 2012 Jun 1; 118(11):2780-6. PMID: 22614656.
      View in: PubMed
    95. Le-Petross HT, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson EF, Harrell RK, Reed BJ, Yang WT. MRI features of inflammatory breast cancer. AJR Am J Roentgenol. 2011 Oct; 197(4):W769-76. PMID: 21940550.
      View in: PubMed
    96. Yu JQ, Cristofanilli M. Circulating tumor cells and PET. J Nucl Med. 2011 Oct; 52(10):1501-4. PMID: 21911596.
      View in: PubMed
    97. Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Res Treat. 2011 Sep; 129(2):451-8. PMID: 21710134.
      View in: PubMed
    98. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 2011 Dec 15; 117(24):5476-84. PMID: 21713757.
      View in: PubMed
    99. Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol. 2012 Apr; 17(2):96-104. PMID: 21671160.
      View in: PubMed
    100. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011; 13(3):R67. PMID: 21699723.
      View in: PubMed
    101. Hayashi N, Nakamura S, Tokuda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. Int J Clin Oncol. 2012 Feb; 17(1):55-62. PMID: 21607830.
      View in: PubMed
    102. De Giorgi U, Cohen EN, Gao H, Mego M, Lee BN, Lodhi A, Cristofanilli M, Lucci A, Reuben JM. Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow. Cancer Biol Ther. 2011 May 1; 11(9):812-5. PMID: 21358274.
      View in: PubMed
    103. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer. 2012 Feb 15; 130(4):808-16. PMID: 21387303.
      View in: PubMed
    104. Swaby RF, Cristofanilli M. Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med. 2011; 9:43. PMID: 21510857.
      View in: PubMed
    105. Dawood S, Cristofanilli M. Inflammatory breast cancer: what progress have we made? Oncology (Williston Park). 2011 Mar; 25(3):264-70, 273. PMID: 21548470.
      View in: PubMed
    106. Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang X, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A, Woodward WA. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44?CD24lo cancer stem cell phenotype. Eur J Cancer. 2011 Jul; 47(10):1527-36. PMID: 21334874.
      View in: PubMed
    107. Dushkin H, Cristofanilli M. Inflammatory breast cancer. J Natl Compr Canc Netw. 2011 Feb; 9(2):233-40; quiz 241. PMID: 21310844.
      View in: PubMed
    108. Ergin AB, Cristofanilli M, Daw H, Tahan G, Gong Y. Recurrent granulomatous mastitis mimicking inflammatory breast cancer. BMJ Case Rep. 2011; 2011. PMID: 22715267.
      View in: PubMed
    109. Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. Int J Clin Oncol. 2011 Oct; 16(5):596-600. PMID: 21210173.
      View in: PubMed
    110. Robertson FM, Cristofanilli M. A global approach to inflammatory breast cancer. Future Oncol. 2011 Jan; 7(1):25-30. PMID: 21174535.
      View in: PubMed
    111. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat. 2011 Feb; 125(3):785-95. PMID: 21153052.
      View in: PubMed
    112. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011 May 1; 117(9):1819-26. PMID: 21509759.
      View in: PubMed
    113. Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer. 2011 Jul 15; 129(2):417-23. PMID: 20857493.
      View in: PubMed
    114. Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer--clinical applications. Nat Rev Clin Oncol. 2010 Dec; 7(12):693-701. PMID: 20956980.
      View in: PubMed
    115. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno NT, Ueno N, Cristofanilli M. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010 Nov-Dec; 60(6):351-75. PMID: 20959401.
      View in: PubMed
    116. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol. 2010 Oct 1; 28(28):4316-23. PMID: 20805453.
      View in: PubMed
    117. Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, Spaeth E, Xu W, Zhang X, Lewis MT, Reuben JM, Krishnamurthy S, Ferrari M, Gaspar R, Buchholz TA, Cristofanilli M, Marini F, Andreeff M, Woodward WA. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One. 2010; 5(8):e12180. PMID: 20808935.
      View in: PubMed
    118. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010 Aug; 51(8):1213-8. PMID: 20660382.
      View in: PubMed
    119. Robertson FM, Ogasawara MA, Ye Z, Chu K, Pickei R, Debeb BG, Woodward WA, Hittelman WN, Cristofanilli M, Barsky SH. Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. J Biomol Screen. 2010 Aug; 15(7):820-9. PMID: 20639504.
      View in: PubMed
    120. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010 Jul 15; 116(14):3330-7. PMID: 20564098.
      View in: PubMed
    121. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, Reuben JM, Lewis MT, Woodward WA. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer. 2010; 9:180. PMID: 20615238.
      View in: PubMed
    122. Dawood S, Gong Y, Broglio K, Buchholz TA, Woodward W, Lucci A, Valero V, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. Breast J. 2010 Sep-Oct; 16(5):529-32. PMID: 20626396.
      View in: PubMed
    123. Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol. 2010 Jul 10; 28(20):3248-55. PMID: 20530274.
      View in: PubMed
    124. Cristofanilli M, Buchholz TA. Proceedings of the First International Inflammatory Breast Cancer Conference. Cancer. 2010 Jun 1; 116(11 Suppl):2729. PMID: 20503400.
      View in: PubMed
    125. Robertson FM, Woodward WA, Pickei R, Ye Z, Bornmann W, Pal A, Peng Z, Hall CS, Cristofanilli M. Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. Cancer. 2010 Jun 1; 116(11 Suppl):2760-7. PMID: 20503408.
      View in: PubMed
    126. Robertson FM, Simeone AM, Lucci A, McMurray JS, Ghosh S, Cristofanilli M. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer. 2010 Jun 1; 116(11 Suppl):2806-14. PMID: 20503412.
      View in: PubMed
    127. Cristofanilli M. Novel targeted therapies in inflammatory breast cancer. Cancer. 2010 Jun 1; 116(11 Suppl):2837-9. PMID: 20503416.
      View in: PubMed
    128. Gazzaniga P, Naso G, Gradilone A, Cortesi E, Gandini O, Gianni W, Fabbri MA, Vincenzi B, di Silverio F, Frati L, Aglianò AM, Cristofanilli M. Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. Int J Cancer. 2010 May 15; 126(10):2437-47. PMID: 19821489.
      View in: PubMed
    129. Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J. 2010 May-Jun; 16(3):327-30. PMID: 20408820.
      View in: PubMed
    130. Cristofanilli M, Braun S. Circulating tumor cells revisited. JAMA. 2010 Mar 17; 303(11):1092-3. PMID: 20233831.
      View in: PubMed
    131. Singh B, Cook KR, Martin C, Huang EH, Mosalpuria K, Krishnamurthy S, Cristofanilli M, Lucci A. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis. 2010 Apr; 27(4):233-40. PMID: 20229045.
      View in: PubMed
    132. Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010 Mar 15; 16(6):1904-14. PMID: 20215537.
      View in: PubMed
    133. Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys. 2010 Mar 1; 76(3):889-95. PMID: 20159363.
      View in: PubMed
    134. Badr H, Carmack CL, Kashy DA, Cristofanilli M, Revenson TA. Dyadic coping in metastatic breast cancer. Health Psychol. 2010 Mar; 29(2):169-80. PMID: 20230090.
      View in: PubMed
    135. Alvarez RH, Booser DJ, Cristofanilli M, Sahin AA, Strom EA, Guerra L, Kau SW, Gonzalez-Angulo AM, Hortobagyi GN, Valero V. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer. 2010 Mar 1; 116(5):1210-7. PMID: 20082452.
      View in: PubMed
    136. Andreopoulou E, Cristofanilli M. Circulating tumor cells as prognostic marker in metastatic breast cancer. Expert Rev Anticancer Ther. 2010 Feb; 10(2):171-7. PMID: 20131993.
      View in: PubMed
    137. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer. 2010 Feb; 10(1):46-51. PMID: 20133258.
      View in: PubMed
    138. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, Hortobagyi GN, Hung MC, Pusztai L, Delaloge S, Michiels S, Cristofanilli M. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist. 2009 Dec; 14(12):1182-8. PMID: 19939894.
      View in: PubMed
    139. Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res Treat. 2010 Aug; 123(1):51-8. PMID: 19902352.
      View in: PubMed
    140. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res. 2009 Nov 1; 15(21):6639-48. PMID: 19825949.
      View in: PubMed
    141. Cristofanilli M. The biological information obtainable from circulating tumor cells. Breast. 2009 Oct; 18 Suppl 3:S38-40. PMID: 19914540.
      View in: PubMed
    142. Woodward WA, Cristofanilli M. Inflammatory breast cancer. Semin Radiat Oncol. 2009 Oct; 19(4):256-65. PMID: 19732690.
      View in: PubMed
    143. Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y. Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. Int J Radiat Oncol Biol Phys. 2009 Aug 1; 74(5):1580-91. PMID: 19540073.
      View in: PubMed
    144. Hayes DF, Cristofanilli M. Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009 Jun 16; 101(12):894-5; author reply 896-7. PMID: 19509356.
      View in: PubMed
    145. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol. 2009 Jul; 6(7):387-94. PMID: 19468291.
      View in: PubMed
    146. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN, Yu D. Breast cancer metastasis: challenges and opportunities. Cancer Res. 2009 Jun 15; 69(12):4951-3. PMID: 19470768.
      View in: PubMed
    147. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009 Jul 10; 27(20):3303-11. PMID: 19451443.
      View in: PubMed
    148. Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WK, Liu TJ. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. 2009 Sep; 94(2):229-34. PMID: 19267183.
      View in: PubMed
    149. Khalifeh I, Deavers MT, Cristofanilli M, Coleman RL, Malpica A, Gilcrease MZ. Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J. 2009 Mar-Apr; 15(2):176-81. PMID: 19292804.
      View in: PubMed
    150. Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM, Ferrari M. Nanotechnology for breast cancer therapy. Biomed Microdevices. 2009 Feb; 11(1):49-63. PMID: 18663578.
      View in: PubMed
    151. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, Yang WT. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009 Feb; 50(2):231-8. PMID: 19164229.
      View in: PubMed
    152. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Inoue T, Macapinlac HA. Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT. Eur J Nucl Med Mol Imaging. 2009 Jun; 36(6):894-902. PMID: 19156410.
      View in: PubMed
    153. Cristofanilli M, Krishnamurthy S, Das CM, Reuben JM, Spohn W, Noshari J, Becker F, Gascoyne PR. Dielectric cell separation of fine needle aspirates from tumor xenografts. J Sep Sci. 2008 Dec; 31(21):3732-9. PMID: 18958846.
      View in: PubMed
    154. Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res. 2008 Dec 1; 14(23):7909-16. PMID: 19047121.
      View in: PubMed
    155. Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer. 2008 Nov 1; 113(9):2422-30. PMID: 18785255.
      View in: PubMed
    156. De Giorgi U, Perkins GH, Cristofanilli M. Risk of ipsilateral lung cancer after postmastectomy radiotherapy and smoking: does the possible triumph over the actual? J Clin Oncol. 2008 Aug 20; 26(24):4044-5; author reply 4045. PMID: 18711199.
      View in: PubMed
    157. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug; 155(2):231-6. PMID: 19482312.
      View in: PubMed
    158. Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L, Cristofanilli M. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat. 2009 Sep; 117(1):61-8. PMID: 18663571.
      View in: PubMed
    159. Cristofanilli M, Reuben J, Uhr J. Circulating tumor cells in breast cancer: fiction or reality? J Clin Oncol. 2008 Jul 20; 26(21):3656-7; author reply 3657-8. PMID: 18640950.
      View in: PubMed
    160. Rao R, Kuerer H, Cristofanilli M, Brigilio K, Shukla S, Rao M, Krishnamurthy S. Breast cancer in the asian Indian population of the United States: a call for screening and education. Breast J. 2008 Jul-Aug; 14(4):402-3. PMID: 18540951.
      View in: PubMed
    161. Jeruss JS, Newman LA, Ayers GD, Cristofanilli M, Broglio KR, Meric-Bernstam F, Yi M, Waljee JF, Ross MI, Hunt KK. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer. 2008 Jun 15; 112(12):2646-54. PMID: 18442039.
      View in: PubMed
    162. Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer. 2008 May 1; 112(9):1905-11. PMID: 18300243.
      View in: PubMed
    163. Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008 Oct 1; 72(2):474-84. PMID: 18439768.
      View in: PubMed
    164. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008 Apr; 247(1):189-96. PMID: 18372468.
      View in: PubMed
    165. Reuben JM, Krishnamurthy S, Woodward W, Cristofanilli M. The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response. Expert Opin Med Diagn. 2008 Apr; 2(4):339-48. PMID: 23495703.
      View in: PubMed
    166. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN, Cristofanilli M. Prognostic value of body mass index in locally advanced breast cancer. Clin Cancer Res. 2008 Mar 15; 14(6):1718-25. PMID: 18347172.
      View in: PubMed
    167. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. 2009 Feb; 113(3):501-7. PMID: 18327638.
      View in: PubMed
    168. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1275-81. PMID: 18250347.
      View in: PubMed
    169. Cristofanilli M. Inflammatory breast cancer: defining a new entity. Semin Oncol. 2008 Feb; 35(1):6. PMID: 18308139.
      View in: PubMed
    170. Singletary SE, Cristofanilli M. Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol. 2008 Feb; 35(1):7-10. PMID: 18308140.
      View in: PubMed
    171. Dawood S, Ueno NT, Cristofanilli M. The medical treatment of inflammatory breast cancer. Semin Oncol. 2008 Feb; 35(1):64-71. PMID: 18308147.
      View in: PubMed
    172. Kurihara H, Yang DJ, Cristofanilli M, Erwin WD, Yu DF, Kohanim S, Mendez R, Kim EE. Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumors. Appl Radiat Isot. 2008 Sep; 66(9):1175-82. PMID: 18308577.
      View in: PubMed
    173. Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobágyi GN, Gonzalez-Angulo AM. Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist. 2008 Jan; 13(1):6-15. PMID: 18245008.
      View in: PubMed
    174. Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S, Cristofanilli M. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol. 2008; 7(4):299-312. PMID: 19227010.
      View in: PubMed
    175. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007 Oct 1; 110(7):1436-44. PMID: 17694554.
      View in: PubMed
    176. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortobágyi GN. Trends for inflammatory breast cancer: is survival improving? Oncologist. 2007 Aug; 12(8):904-12. PMID: 17766649.
      View in: PubMed
    177. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008 Jun; 109(3):417-26. PMID: 17653852.
      View in: PubMed
    178. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer. 2007 Jun 15; 109(12):2392-404. PMID: 17503430.
      View in: PubMed
    179. Woodward WA, Lucci A, Cristofanilli M. A gene signature in breast cancer. N Engl J Med. 2007 May 3; 356(18):1887-8; author reply 1887-8. PMID: 17479476.
      View in: PubMed
    180. Dawood S, Cristofanilli M. What progress have we made in managing inflammatory breast cancer? Oncology (Williston Park). 2007 May; 21(6):673-9; discussion 679-80, 686-7. PMID: 17564325.
      View in: PubMed
    181. Pusztai L, Cristofanilli M, Paik S. New generation of molecular prognostic and predictive tests for breast cancer. Semin Oncol. 2007 Apr; 34(2 Suppl 3):S10-6. PMID: 17512431.
      View in: PubMed
    182. Dawood S, Cristofanilli M. Integrating circulating tumor cell assays into the management of breast cancer. Curr Treat Options Oncol. 2007 Feb; 8(1):89-95. PMID: 17634836.
      View in: PubMed
    183. Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer. 2007 Feb 1; 109(3):496-501. PMID: 17149760.
      View in: PubMed
    184. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007 Feb 1; 13(3):920-8. PMID: 17289886.
      View in: PubMed
    185. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007 Feb; 7(6):471-9. PMID: 17386124.
      View in: PubMed
    186. Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M. Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer. 2006 Dec; 7(5):396-400. PMID: 17239264.
      View in: PubMed
    187. Cristofanilli M, Mendelsohn J. Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy? Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17073-4. PMID: 17090687.
      View in: PubMed
    188. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006 Nov 1; 12(21):6403-9. PMID: 17085652.
      View in: PubMed
    189. Gonzalez-Angulo AM, Guarneri V, Gong Y, Cristofanilli M, Morales-Vasquez F, Sneige N, Hortobagyi GN, Esteva FJ. Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. Clin Breast Cancer. 2006 Oct; 7(4):326-30. PMID: 17092400.
      View in: PubMed
    190. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van Wart Hood J, Valero V, Hortobagyi GN. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer. 2006 Sep 1; 107(5):935-44. PMID: 16874816.
      View in: PubMed
    191. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4218-24. PMID: 16857794.
      View in: PubMed
    192. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006 Jun; 33(3 Suppl 9):S9-14. PMID: 16797376.
      View in: PubMed
    193. Yang CH, Cristofanilli M. The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer. Future Oncol. 2006 Apr; 2(2):247-55. PMID: 16563093.
      View in: PubMed
    194. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006 Mar 1; 106(5):1000-6. PMID: 16444747.
      View in: PubMed
    195. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006 Mar 1; 24(7):1037-44. PMID: 16505422.
      View in: PubMed
    196. Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res. 2005 Dec 1; 11(23):8398-402. PMID: 16322301.
      View in: PubMed
    197. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005 Oct 1; 23(28):7098-104. PMID: 16192593.
      View in: PubMed
    198. Chedid S, Rivera E, Frye DK, Ibrahim N, Esteva F, Valero V, Hortobagyi G, Mettinger KL, Cristofanilli M. Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006 Apr; 57(4):540-4. PMID: 16193332.
      View in: PubMed
    199. Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau SW, Hortobagyi GN, Rivera E. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005 Sep 15; 104(6):1158-71. PMID: 16047352.
      View in: PubMed
    200. Diaz LK, Cristofanilli M, Zhou X, Welch KL, Smith TL, Yang Y, Sneige N, Sahin AA, Gilcrease MZ. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol. 2005 Sep; 18(9):1165-75. PMID: 15920552.
      View in: PubMed
    201. Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer. 2005 Aug 15; 104(4):676-81. PMID: 15981280.
      View in: PubMed
    202. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15; 11(16):5678-85. PMID: 16115903.
      View in: PubMed
    203. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 1; 23(25):5983-92. PMID: 16087943.
      View in: PubMed
    204. Shen J, Hunt KK, Mirza NQ, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Ross MI, Ames FC, Feig BW, Singletary SE, Cristofanilli M, Meric-Bernstam F. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer. 2005 Aug 1; 104(3):479-90. PMID: 15968686.
      View in: PubMed
    205. Gonzalez-Angulo AM, Morandi P, Cristofanilli M. Inflammatory breast cancer and high-dose chemotherapy: back to the past. J Clin Oncol. 2005 Jun 1; 23(16):3859-60; author reply 3860-2. PMID: 15923586.
      View in: PubMed
    206. Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res. 2005 May 1; 11(9):3309-14. PMID: 15867228.
      View in: PubMed
    207. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res. 2005 May 1; 11(9):3315-9. PMID: 15867229.
      View in: PubMed
    208. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005 Mar 15; 103(6):1122-8. PMID: 15712375.
      View in: PubMed
    209. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005 Mar 1; 23(7):1420-30. PMID: 15735118.
      View in: PubMed
    210. Cristofanilli M. The "microscopic" revolution in breast carcinoma. Cancer. 2005 Mar 1; 103(5):877-80. PMID: 15611972.
      View in: PubMed
    211. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 1; 23(16):3676-85. PMID: 15738535.
      View in: PubMed
    212. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, Hortobagyi GN. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005 Jan 1; 23(1):41-8. PMID: 15625359.
      View in: PubMed
    213. Yang CH, Cristofanilli M. Systemic treatments for inflammatory breast cancer. Breast Dis. 2005-2006; 22:55-65. PMID: 16735787.
      View in: PubMed
    214. Krishnamurthy S, Zhao L, Hayes K, Glassman AB, Cristofanilli M, Singletary SE, Hunt KK, Kuerer HM, Sneige N. Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study. Cancer. 2004 Oct 25; 102(5):322-7. PMID: 15376199.
      View in: PubMed
    215. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, Smith TL, Hortobagyi GN. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer. 2004 Oct 15; 101(8):1760-6. PMID: 15386311.
      View in: PubMed
    216. Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, Yamamura Y, Hortobagyi GN, Cristofanilli M. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6215-21. PMID: 15448010.
      View in: PubMed
    217. Resetkova E, Gonzalez-Angulo AM, Sneige N, Mcdonnell TJ, Buzdar AU, Kau SW, Yamamura Y, Reuben JM, Hortobagyi GN, Cristofanilli M. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer. 2004 Sep 1; 101(5):913-7. PMID: 15329897.
      View in: PubMed
    218. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19; 351(8):781-91. PMID: 15317891.
      View in: PubMed
    219. Shen J, Valero V, Buchholz TA, Singletary SE, Ames FC, Ross MI, Cristofanilli M, Babiera GV, Meric-Bernstam F, Feig B, Hunt KK, Kuerer HM. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol. 2004 Sep; 11(9):854-60. PMID: 15313733.
      View in: PubMed
    220. Yared MA, Middleton LP, Meric F, Cristofanilli M, Sahin AA. Expression of c-kit proto-oncogene product in breast tissue. Breast J. 2004 Jul-Aug; 10(4):323-7. PMID: 15239791.
      View in: PubMed
    221. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004 Feb; 4(6):415-9. PMID: 15023242.
      View in: PubMed
    222. Cristofanilli M, Singletary ES, Hortobagyi GN. Inflammatory breast carcinoma: the sphinx of breast cancer research. J Clin Oncol. 2004 Jan 15; 22(2):381-3; author reply 383. PMID: 14722054.
      View in: PubMed
    223. Cristofanilli M, Hortobágyi GN. Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective. Oncologist. 2004; 9(4):471-8. PMID: 15266101.
      View in: PubMed
    224. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res. 2003 Nov 15; 9(15):5652-9. PMID: 14654548.
      View in: PubMed
    225. Esteva FJ, Rivera E, Cristofanilli M, Valero V, Royce M, Duggal A, Colucci P, DeJager R, Hortobagyi GN. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer. 2003 Sep 1; 98(5):900-7. PMID: 12942555.
      View in: PubMed
    226. Chagpar A, Meric-Bernstam F, Hunt KK, Ross MI, Cristofanilli M, Singletary SE, Buchholz TA, Ames FC, Marcy S, Babiera GV, Feig BW, Hortobagyi GN, Kuerer HM. Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol. 2003 Jul; 10(6):628-34. PMID: 12839847.
      View in: PubMed
    227. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15. PMID: 12855612.
      View in: PubMed
    228. Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res. 2003 Jul; 9(7):2426-34. PMID: 12855614.
      View in: PubMed
    229. Krishnamurthy S, Sneige N, Thompson PA, Marcy SM, Singletary SE, Cristofanilli M, Hunt KK, Kuerer HM. Nipple aspirate fluid cytology in breast carcinoma. Cancer. 2003 Apr 25; 99(2):97-104. PMID: 12704689.
      View in: PubMed
    230. Kuerer HM, Thompson PA, Krishnamurthy S, Fritsche HA, Marcy SM, Babiera GV, Singletary SE, Cristofanilli M, Sneige N, Hunt KK. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. Clin Cancer Res. 2003 Feb; 9(2):601-5. PMID: 12576424.
      View in: PubMed
    231. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003 Jan-Feb; 9(1):33-41. PMID: 12602766.
      View in: PubMed
    232. Cristofanilli M, Buzdar AU, Hortobágyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003; 8(2):141-8. PMID: 12697939.
      View in: PubMed
    233. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol. 2003 Jan; 21(1):57-63. PMID: 12496764.
      View in: PubMed
    234. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol. 2002 Oct; 12(4):319-28. PMID: 12382190.
      View in: PubMed
    235. Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov. 2002 Jun; 1(6):415-26. PMID: 12119743.
      View in: PubMed
    236. Rivera E, Valero V, Cristofanilli M, Frye DK, Booser DJ, Rosales MM, Hortobagyi GN. Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma. Cancer. 2002 May 1; 94(9):2321-6. PMID: 12015755.
      View in: PubMed
    237. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Apr 1; 20(7):1800-8. PMID: 11919237.
      View in: PubMed
    238. Cristofanilli M, De Gasperis G, Zhang L, Hung MC, Gascoyne PR, Hortobagyi GN. Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. Clin Cancer Res. 2002 Feb; 8(2):615-9. PMID: 11839684.
      View in: PubMed
    239. Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z, Booser DJ, Hortobagyi GN. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol. 2002 Apr; 49(4):299-302. PMID: 11914909.
      View in: PubMed
    Cristofanilli's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _